Oleogel-S10 for Inherited Epidermolysis Bullosa
Oleogel-S10 is a topical gel and is being developed as a prescription medicine as for EB, for which there are limited treatment options. Oleogel-S10 causes the keratinocytes (cells that regenerate the outer layer of the skin) to migrate (move across the wound) and become mature epithelial skin cells, resulting in rapid wound healing. If licensed, oleogel-S10 will offer a treatment option for wound care in patients with EB who currently have limited therapies available.
Dupilumab for Children Aged 12 Years to 17 Years with Moderate to Severe Atopic Dermatitis
Dupilumab is a monoclonal antibody medicine that is currently in development as an injection under the skin (subcutaneous) for the treatment of moderate to severe AD in children. Dupilumab is already licensed in the UK for the treatment of moderate-to-severe atopic dermatitis in adults. If licensed, dupilumab will offer an additional treatment option for children aged 12 years to 17 years with moderate to severe atopic dermatitis uncontrolled on current therapies.
Rituximab for Pemphigus Vulgaris
Corticosteriods (anti-inflammatory medicines) are usually used for the treatment of PV. Most people will need to take corticosteroids in addition to another medication to help improve the effectiveness and minimise the doses and side effects of corticosteroids. Rituximab is currently being investigated as a treatment option for PV. Rituximab binds specifically to a protein called CD20 located on pre-B and mature B lymphocytes inducing death of these cells. If licensed, rituximab may offer an additional treatment option for patients with PV after failure of systemic steroids and steroid sparing agents to control the disease.
Rexmyelocel-T for critical limb ischaemia in patients with diabetes mellitus
The treatment, rexmyelocel-T, is being developed to relieve leg pain at rest and heal leg ulcers. The treatment uses cells from bone marrow which are injected into the damaged blood vessel, where they restore existing blood vessels and create new blood vessels. By improving the blood flow in the limb, this treatment aims to …
Certolizumab pegol (Cimzia) for chronic plaque psoriasis in adults
Certolizumab pegol is an anti-TNF (anti-tumour necrosis factor) drug. It works by blocking the action of TNF protein and which reduces inflammation. It is currently licensed for the treatment of several chronic inflammatory conditions, including Crohn’s Disease, rheumatoid arthritis, psoriatic arthritis and juvenile arthritis. If licensed for chronic plaque psoriasis in adults it will offer …
Cryopreserved human placental tissue (Stravix) for wound repair
Cryopreserved human placental tissue is a new treatment to aid the healing of wounds that may reduce inflammation and scarring. Skin damage through cuts, burns or surgery are a source of discomfort, inflammation and scarring, and can also lead to infections. Cryopreserved human placental tissue includes molecules and materials expected to aid wound healing as …